SCHEMBL25186768

SCHEMBL25186768

CC(C)c1ncc(/C=C/c2ccccc2)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.42
▸ BRD9 Q9H8M2 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ PPARA Q07869 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.38
▸ METAP1 P53582 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ S1PR3 Q99500 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ ELANE P08246 2/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ IDO1 P14902 1/20 0.38
▸ GABRB1 P18505 1/20 0.38
▸ GABRB2 P47870 1/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25189635 0.84 AAK1 (0.37) BRD9BRD4RXFP1METAP1EGFR
SCHEMBL25186778 0.77 LCK (0.39) BRD9BRD4RXFP1METAP1EGFR
SCHEMBL28773311 0.75 EGFR (0.44) TRPV1BRD9RXFP1EGFRHDAC3
SCHEMBL25186762 0.72 RAB9A (0.48) MAPK1RAB9A
SCHEMBL30419303 0.72 RAB9A (0.48) MAPK1RAB9A
SCHEMBL25524778 0.71 RXFP1 (0.36) BRD9BRD4RXFP1METAP1MAPK1
SCHEMBL2880191 0.71 LMNA (0.54) BRD9BRD4RXFP1METAP1CNR2
SCHEMBL2737224 0.70 NLRP3 (0.56) RXFP1IDO1
SCHEMBL10281753 0.70 HPGD (0.45) TRPV1BRD9RXFP1HDAC3HDAC1
SCHEMBL25195653 0.70 AHR (0.58) TRPV1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA BOSTON INC. 2025-05-01 — — US disclosed
EP-4430028-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) 2024-09-18 — — EP disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 — — WO disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF AHR, ARNT, NR1H2 TRPV1 462/4885BRD9 1457/4885BRD4 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback